PlainPharmaWatch

CMS Open Payments · Tool

Calliditas Therapeutics US Inc. vs Omnia Medical, LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Omnia Medical, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,054, versus 169 for the other company. Its single largest recorded recipient represents 17.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Calliditas Therapeutics US Inc.
HHI 169 · top recipient 6.2%
Ranked #1,593 of 1,838 companies by HHI
Omnia Medical, LLC
HHI 1,054 · top recipient 17.8%
Ranked #1,007 of 1,838 companies by HHI

Payment Overview

Total Payments
$2.0M
% of Industry
0.0%
Transactions
12,052
Avg per Transaction
$165.74
Recipients
12,051
Avg per Recipient
$165.75
Payment Types
6
Top Payment Type
Honoraria
Company B

Omnia Medical, LLC

Total Payments
$2.0M
% of Industry
0.0%
Transactions
110
Avg per Transaction
$18.3K
Recipients
110
Avg per Recipient
$18.3K
Payment Types
3
Top Payment Type
Acquisitions

Highlighted values indicate the higher figure for each metric.

Total payments compared

Calliditas Therapeutics US Inc. vs Omnia Medical, LLC - total reported payments in CMS Open Payments PY2024

Omnia Medical, LLC$2.0MCalliditas Therapeutics US…$2.0M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Calliditas Therapeutics US Inc.

Honoraria $878.3K

44.2%

Consulting Fee $472.9K

23.8%

Food and Beverage $353.3K

17.8%

Travel and Lodging $280.4K

14.1%

Space Rental or Facility Fees $1.5K

0.1%

Education $250.00

0.0%

Omnia Medical, LLC

Acquisitions $1.4M

68.8%

Royalty or License $530.1K

26.3%

Consulting Fee $99.1K

4.9%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Calliditas Therapeutics US Inc.

  1. 1

    GERALD BERNARD APPEL

    $122,899.83 · 94 txns

  2. 2

    JORGE ANTONIO LARRANAGA

    $106,250.71 · 102 txns

  3. 3

    SREEDHAR A MANDAYAM

    $74,332.61 · 97 txns

  4. 4

    ANIS A RAUF

    $69,181.56 · 80 txns

  5. 5

    SAYNA NOROUZI

    $68,439.72 · 58 txns

Omnia Medical, LLC

  1. 1

    JOHN MAIN

    $360,000.00 · 12 txns

  2. 2

    BRIAN SNELL

    $297,000.00 · 1 txns

  3. 3

    ANDREW PARKINSON

    $252,879.70 · 10 txns

  4. 4

    IAN JOHNSON

    $240,000.00 · 4 txns

  5. 5

    JUSTIN FIELD

    $168,833.36 · 7 txns

Summary Comparison

Metric Calliditas Therapeutics US Inc. Omnia Medical, LLC
Total Payments $2.0M $2.0M
% of Industry Total 0.0% 0.0%
Transaction Count 12,052 110
Avg per Transaction $165.74 $18.3K
Recipient Count 12,051 110
Avg per Recipient $165.75 $18.3K
Payment Type Count 6 3
Top Payment Type Honoraria Acquisitions

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.